Catalyst Wire Dossier Catalyst Wire Dossier

Sebetralstat (KVD900)

sebetralstat · KalVista Pharmaceuticals, Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sebetralstat (KVD900), covering 2024-07-19 to 2024-07-19. Get the full timeline:

Most recent: Clinical Trial Update: A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) [Phase 3]

See pricing